SCHEMBL1103587

SCHEMBL1103587

c1ccc(-c2c3ccccc3c(-c3cccc4ccccc34)c3c2cnc2ccccc23)nc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 5/20 0.46
▸ ALDH1A1 P00352 4/20 0.46
▸ TP53 P04637 3/20 0.46
▸ SMN1; SMN2 Q16637 3/20 0.46
▸ NPC1 O15118 3/20 0.46
▸ MAPT P10636 3/20 0.46
▸ HPGD P15428 3/20 0.46
▸ MAPK1 P28482 2/20 0.46
▸ HSD17B10 Q99714 2/20 0.46
▸ TGFBR1 P36897 7/20 0.43
▸ HTR2C P28335 1/20 0.41
▸ DCTPP1 Q9H773 1/20 0.40
▸ GPR3 P46089 1/20 0.39
▸ MAPK14 Q16539 5/20 0.39
▸ TGFBR2 P37173 1/20 0.39
▸ ABL2 P42684 1/20 0.39
▸ CSNK1A1 P48729 1/20 0.39
▸ CSNK1D P48730 1/20 0.39
▸ MAP3K20 Q9NYL2 1/20 0.39
▸ LMNA P02545 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1103247 0.89 KDM4E (0.46) KDM4EALDH1A1TP53SMN1; SMN2NPC1
SCHEMBL1103468 0.87 KDM4E (0.44) KDM4EALDH1A1TP53SMN1; SMN2NPC1
SCHEMBL1103254 0.85 KDM4E (0.43) KDM4EALDH1A1TP53SMN1; SMN2NPC1
SCHEMBL1103569 0.85 KDM4E (0.42) KDM4EALDH1A1TP53SMN1; SMN2NPC1
SCHEMBL1103591 0.84 NPC1 (0.41) KDM4ENPC1GPR3L3MBTL1TDP1
SCHEMBL1103592 0.84 BCHE (0.40) KDM4EALDH1A1SMN1; SMN2NPC1MAPT
SCHEMBL1103557 0.83 KDM4E (0.41) KDM4EALDH1A1TP53SMN1; SMN2NPC1
SCHEMBL1103466 0.83 KDM4E (0.41) KDM4EALDH1A1TP53SMN1; SMN2NPC1
SCHEMBL1103360 0.83 KDM4E (0.43) KDM4EALDH1A1TP53SMN1; SMN2NPC1
SCHEMBL17227621 0.82 KDM4E (0.58) KDM4EALDH1A1TP53SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 — — US disclosed
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 — — US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 — — US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same ORMDL3, OCIAD2, OCIAD1 KDM4E 3367/4885ALDH1A1 1015/4885TP53 3456/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback